- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
NPS Pharmaceuticals Inc
+ Add to WatchlistNPSP:US
14.2800 USD 0.5300 3.85%
Share
As of 20:10:00 ET on 05/17/2013.
More on NPSP
News for NPS Pharmaceuticals Inc (NPSP)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Orphan Drug Prices Under Siege in Austerity-Minded Europe
- U.S. Stock Options With Biggest Changes in Implied Volatility
- NPS Buys Back Rights to Gattex From Takeda to Spur Sales
- U.S. Stock Options With Biggest Changes in Implied Volatility
- NPS's Nader on Drug Research, Growth Strategy
- Largest Nasdaq Short Interest Changes as of Dec. 31
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- NPS Gattex Wins Approval for Short-Bowel Syndrome
- Drug Stocks Prey for Insiders as Industry Resists Change
- NPS Jumps as FDA Staff Backs Risk Plan for Bowel Drug
- NPS Bowel Drug Gattex’s Risk Plan Gains FDA Staff Support
- U.S. Stock Options With Biggest Changes in Implied Volatility
- NPS Pharmaceuticals President and CEO Dr. Francois Nader Recognized as Regional Finalist for Ernst & Young Entrepreneur of the Published May 16, 2013
- NPS Pharmaceuticals Recognized by National Organization for Rare Disorders for Gattex® as an Innovative Treatment for Patients Published May 15, 2013
- National Organization for Rare Disorders to Celebrate 30 Years of Achievement and Promote a Promising Future for the Rare Published May 10, 2013
- NPS Pharmaceuticals Reports First Quarter 2013 Financial Results Published May 09, 2013
- NPS Pharmaceuticals to Report First Quarter 2013 Financial Results Published May 01, 2013
- BioNJ To Host 2ND Annual Life Sciences Industry HR Conference on May 20 Published Apr 30, 2013
- NPS Pharmaceuticals Among 100 Best Places to Work in New Jersey for Second Consecutive Year Published Apr 26, 2013
- NPS Pharmaceuticals to Present at Needham Healthcare Conference Published Apr 22, 2013
- Puma Biotech Gains After Rival Drug Data Show No Threat
- Merck KGaA Doesn’t Rule Out Pursuing Lung-Cancer Vaccine
- Billionaire Frost Props Up Prolor Bid With Stock Buys
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Gene-Testing Dispute Focuses on How Much a Patient Should Know
- Tennis With Evert, Baseball With Microsoft: D.C. Scene
- ReNeuron Plans to Report Stroke Patients Helped, CEO Says
- Roche Experimental Leukemia Drug Helps Shrink Tumors
- Glenview Capital Mgmt Inc Holdings in 1st Quarter: 13F Alert
- Sirios Capital Management Holdings in 1st Quarter: 13F Alert
- Bayer, Algeta Win U.S. Approval for Prostate Cancer Drug
- BASF Reaches Enzyme-Platform Licensing Accord With Dyadic
- Manatt, Jones Day, Howrey, Ropes & Gray: Business of Law
- Roche Wins FDA Approval for Test to Target Lung Cancer
- Primecap Rides Health to Top Growth Fund: Riskless Return
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page